These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3519155)

  • 1. Some cardiovascular effects of monensin.
    Atef M; Youssef S el-D ; el-Sayed MG; Shalaby MA
    Dtsch Tierarztl Wochenschr; 1986 Feb; 93(2):81-4. PubMed ID: 3519155
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of the carboxylic ionophore monensin on regional blood flow in normal and ischemic myocardium in anesthetized dogs.
    Kabell G; Saini RK; Somani P; Pressman BC
    J Pharmacol Exp Ther; 1979 Oct; 211(1):231-7. PubMed ID: 490322
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparison of the cardiovascular, renal, and coronary effects of dopamine and monensin in endotoxic shock.
    Somani P; Saini RK
    Circ Shock; 1981; 8(4):451-64. PubMed ID: 7023738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of amezinium, a novel antihypotensive drug. II. Examination of cardiovascular effects.
    Lehmann HD; Giertz H; Kretzschmar R; Lenke D; von Philipsborn G; Raschack M; Schuster J
    Arzneimittelforschung; 1981; 31(9a):1544-57. PubMed ID: 7197969
    [No Abstract]   [Full Text] [Related]  

  • 5. Direct effects of the monovalent cation ionophores monensin and nigericin on myocardium.
    Sutko JL; Besch HR; Bailey JC; Zimmerman G; Watanabe AM
    J Pharmacol Exp Ther; 1977 Dec; 203(3):685-700. PubMed ID: 925964
    [No Abstract]   [Full Text] [Related]  

  • 6. [An experimental study of the cardio- and hemodynamic effects of the carboxyl ionophore monensin].
    Gurbanov KG; Kovalev GV; Paperno AA
    Farmakol Toksikol; 1990; 53(3):17-9. PubMed ID: 2387374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcellular actions and potential adverse cardiac effects of the cardiotonic ionophore monensin.
    Shlafer M; Kane P
    J Pharmacol Exp Ther; 1980 Sep; 214(3):567-73. PubMed ID: 6249911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular effects and pharmacokinetics of the carboxylic ionophore monensin in dogs and rabbits.
    Fahim M; Pressman BC
    Life Sci; 1981 Nov; 29(19):1959-66. PubMed ID: 7311727
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanism of canine coronary artery relaxation by monensin.
    Anderson HL; Winquist RJ; Webb RC; Bohr DF
    Circ Res; 1983 Aug; 53(2):168-75. PubMed ID: 6309429
    [No Abstract]   [Full Text] [Related]  

  • 10. Monensin potentiation of potassium contracture in cat myocardium.
    Bassett AL; Wiggins JR; Gelband H; Pressman BC
    J Pharmacol Exp Ther; 1978 Dec; 207(3):966-75. PubMed ID: 32383
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of monensin, a Na+-selective carboxylic ionophore, on coronary circulation.
    Somani P; Kabell GG; Saini RK; Hester RK
    Adv Myocardiol; 1980; 2():435-47. PubMed ID: 7423057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Greater oral activity of etilefrine pivalate compared to etilefrine in the cat and dog].
    Eisenburger R; Seibel K; Hampel H
    Arzneimittelforschung; 1985; 35(7):1076-9. PubMed ID: 2864934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview on the pharmacological and toxicological characterization of the calcium antagonist tiapamil.
    Haeusler G; Eigenmann R; Gerold M; Hefti F; Jovanovic D; Blaber L; Nakamura K; Thorens S
    Cardiology; 1982; 69 Suppl():31-57. PubMed ID: 7151083
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Nisoldipine, Bay k 5552).
    Kazda S; Garthoff B; Meyer H; Schlossmann K; Stoepel K; Towart R; Vater W; Wehinger E
    Arzneimittelforschung; 1980; 30(12):2144-62. PubMed ID: 7194077
    [No Abstract]   [Full Text] [Related]  

  • 15. [2-Aryl substituted benzo-anellated 5-ring-heterocycles as potential agents for the cardiovascular system. 2. 1,3-Benzimidazoles].
    Rose U
    Pharmazie; 1991 Nov; 46(11):775-7. PubMed ID: 1811227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive and cardiovascular effects of the new dihydropyridine derivative methyl (E)-3-phenyl-2-propen-1-yl-1,4-dihydro-2,6-dimethyl- 4-(3-nitrophenyl)pyridine-3,5-dicarboxylate.
    Yamaura T; Kase N; Kita H; Uematsu T
    Arzneimittelforschung; 1986; 36(1):29-34. PubMed ID: 3754142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of carboxylic ionophore monensin on atrial contractility and Ca2+ regulation by isolated cardiac microsomes.
    Shlafer M; Somani P; Pressman BC; Palmer RF
    J Mol Cell Cardiol; 1978 Apr; 10(4):333-46. PubMed ID: 347094
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular effects of cimetidine.
    Kato H; Kurihara J; Kasuya Y
    Arch Int Pharmacodyn Ther; 1981 Feb; 249(2):247-56. PubMed ID: 7224724
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro and in vivo assessment of the cardiovascular effects of the cardiotonic drug MDL 19205.
    Roebel LE; Dage RC; Cheng HC; Woodward JK
    J Cardiovasc Pharmacol; 1984; 6(1):43-9. PubMed ID: 6199610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monensin-induced reversal of positive force-frequency relationship in cardiac muscle: role of intracellular sodium in rest-dependent potentiation of contraction.
    Mubagwa K; Lin W; Sipido K; Bosteels S; Flameng W
    J Mol Cell Cardiol; 1997 Mar; 29(3):977-89. PubMed ID: 9152859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.